Caspase inhibitor (Emricasan/IDN-6556; NCT02686762) and apoptosis signaling kinase-1 (ASK-1) inhibitor (Selonsertib/GS-4997; NCT03053050), which target hepatic cell death, are also being evaluated in phase 2b and 3 studies of NASH patients, respectively. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.